Kupffer cell factor mediated depression of hepatic parenchymal cell cytochrome P-450

doi:10.1016/0006-2952(86)90114-0

Biochemical Pharmacology

Volume 35, Issue 9, 1 May 1986, Pages 1491-1497

https://doi.org/10.1016/0006-2952(86)90114-0 Get rights and content

Abstract

Following the administration of latex particles (0.46 μm), cytochrome P-450 dependent monooxygenase system was depressed in the livers of mice. These particles were taken up exclusively by Kupffer cells in the liver, and no particles were found in the hepatocytes which contain most of the monooxygenase capacity in that organ. Cytochrome P-450 was also depressed in isolated hepatocytes incubated with phagocytosing Kupffer cells or the cell free filtrate from an incubation mixture of Kupffer cells and latex particles. Kupffer cells and hepatocytes were then incubated in a double-chambered vessel in which the two cell types were separated by a semi-permeable membrane. When latex particles were added to the chamber containing Kupffer cells, a factor was released which crossed the semipermeable membrane and depressed cytochrome P-450 and benzo[a]pyrene hydroxylase in hepatocytes contained in the other chamber. It is concluded that, during the process of phagocytosis (in vivo or in vitro) by Kupffer cells in the liver, the levels of cytochrome P-450 and related drug biotransformation were depressed in the adjacent parenchymal cells.

References (43)

K.C. Chang et al.
Lancet
(1978)
K.W. Renton
K.W. Renton
K. Renton et al.
Biochem. biophys. Res. Commun.
(1976)
G. Singh et al.
Biochem. biophys. Res. Commun.
(1982)
D. Farquhar et al.
Biochem. Pharmac.
(1976)
L.F. Soyka et al.
Int. J. Immunopharmac.
(1979)
T. Omura et al.
J. biol. Chem.
(1964)
D.W. Nebert et al.
J. biol. Chem.
(1968)
O.H. Lowry et al.
J. biol. Chem.
(1951)

P.O. Seglen

Expl Cell Res.

(1973)

D.N. Skilleter et al.

Chem. Biol. Interact.

(1978)

D. Tracey et al.

Int. J. Immunopharmac.

(1982)

R. Chaby et al.

Int. J. Immunopharmac.

(1982)

D. Farquhar et al.

Biochem. Pharmac.

(1983)

F. Beck et al.

Biochem. Pharmac.

(1973)

T. Tanaka et al.

Int. J. Immunopharmac.

(1979)

M.J. Kraemer et al.

Pediatrics, N.Y.

(1982)

G. Singh et al.

Molec. Pharmac.

(1981)

A. Parkinson et al.

Drug Metab. Dispos.

(1982)

E. Cantrell et al.

J. Cell Biol.

(1972)

Cited by (72)

Cytochrome P450 4F subfamily: At the crossroads of eicosanoid and drug metabolism
2006, Pharmacology and Therapeutics
The cytochrome P450 4F (CYP4F) subfamily has over the last few years come to be recognized for its dual role in modulating the concentrations of eicosanoids during inflammation as well as in the metabolism of clinically significant drugs. The first CYP4F was identified because it catalyzed the hydroxylation of leukotriene B₄ (LTB₄) and since then many additional members of this subfamily have been documented for their distinct catalytic roles and functional significance. Recent evidence emerging in relation to the temporal change of CYP4F expression in response to injury and infection supports an important function for these isozymes in curtailing inflammation. Their tissue-dependent expression, isoform-based catalytic competence and unique response to the external stimuli imply a critical role for them to regulate organ-specific functions. From this standpoint variations in relative CYP4F levels in humans may have direct influence on the metabolic outcome through their ability to generate and/or degrade bioactive eicosanoids or therapeutic agents. This review covers the enzymatic characteristics and regulatory properties of human and rodent CYP4F isoforms and their physiological relevance to major pathways in eicosanoid and drug metabolism.
Chapter 4 Mechanisms of immunotoxic effects
2004, Immunotoxicology of Drugs and Chemicals: an Experimental and Clinical Approach
The immunotoxic effects of drugs and other chemicals are extremely varied and have been shown to affect almost every organ or tissue of the body. This chapter provides an overview of the mechanisms of immunotoxic effects. Overlapping mechanisms can result in diverse adverse effects. The immunotoxic effects are best divided into immunosuppression, immunostimulation, hypersensitivity, and autoimmunity. Although similar immunotoxic mechanisms may impact on the normal immunity to induce a shift toward hyperimmunity and result in either hypersensitivity, autoimmunity, or immunostimulation, the three latter categories are sufficiently different both mechanistically and clinically to justify their individualization as different categories of immunotoxic effects. Over the past 30 years, immunotoxicologists have focused most of their efforts on developing animal models and assay that can be reliable to predict immunotoxicity in nonclinical studies. Despite extensive research to understand the mechanisms involved in the immunotoxicity of a few drugs and chemicals, relatively limited knowledge is available on the mechanisms of immunotoxic effects in general.
Inflammatory prompts produce isoform-specific changes in the expression of leukotriene B<inf>4</inf> ω-hydroxylases in rat liver and kidney
2003, FEBS Letters
Cytochrome P450 (CYP) 4Fs metabolize leukotriene B₄ and other inflammatory mediators in the arachidonic acid cascade. Here we show that lipopolysaccharide (LPS) treatment suppresses CYP4F4 and up-regulates CYP4F5 mRNA expression in rat liver whereas renal CYP4Fs are essentially unchanged. BaSO₄ treatment, in contrast, increases both hepatic and renal CYP4F expression levels. Thus, distinct regulatory mechanisms in CYP4F expression might operate under different inflammatory prompts. To examine hepatic totipotency, primary hepatocytes were treated with varying doses of LPS resulting in decrease in all the CYP4F isoforms. Treatment of hepatocytes with 5 ng/ml of interleukin-1β mimics the in vivo effects of LPS on CYP4F expression.
Expression of cytochromes P450 4F4 and 4F5 in infection and injury models of inflammation
2003, Biochimica et Biophysica Acta - General Subjects
Lipopolysaccharide (LPS) treatment of rats suppresses CYP 4F4 and 4F5 expression by 50 and 40%, respectively, in a direct fashion occurring in the liver. This contention is borne out by essentially parallel dose-dependent changes observed upon treatment of rat hepatocyte cultures with LPS. An alternate avenue of triggering the inflammatory cascade is traumatic brain injury by controlled cortical impact. Such injury brings about a dramatic change in the expression of CYP 4F4 and 4F5 mRNA which reaches its greatest effect 24 h after impact compared with sham-operated but uninjured controls. At time points after 24 h the expression of both isoforms increases dramatically reaching highest levels at 2 weeks post-injury. These changes in mRNA expression are mirrored by changes in protein expression. The results are consistent with the notion that immediately after injury concentrations of leukotriene and prostaglandin mediators are elevated by decreased CYP 4F concentrations. As time after injury increases those conditions reverse. Increased CYP 4F expression leads to diminished concentrations of leukotriene and prostaglandin mediators and then to recovery and repair.
Alteration of drug biotransformation and elimination during infection and inflammation
2001, Pharmacology and Therapeutics
Citation Excerpt :
The loss of drug biotransformation has been studied in a number of different animal models of inflammation, and has been reviewed extensively by Morgan (1997). When particulate matter is phagocytosed, the resultant activation of Kupffer cells leads to a down-regulation of a number of CYP isoforms (Peterson & Renton, 1984, 1986). Agents such as trypan blue dye, zymosan, dextran sulphate, and latex beads have been assumed to lower CYP by activating an inflammatory response within the liver macrophages (Morgan, 1997).
During infection or inflammation, the expression of cytochrome P450 and its dependent biotransformation pathways are modified. This results in a change in the capacity of the liver to handle drugs and in alterations in the production and elimination of endogenous substances throughout the body. The majority of the CYP isoforms are modified at pre-translational steps in protein synthesis, and, in most cases, cytokines are involved as mediators of the response. Recent information suggests that inflammatory responses that are localized to the CNS cause a loss of CYP within the brain. This is accompanied by a parallel down-regulation of CYP in peripheral organs that is mediated by a signaling pathway between the brain and periphery. This review covers the loss that occurs in the major mammalian CYP families in response to infection/inflammation and the mediator pathways that are key to this response.
Kupffer cell-mediated differential down-regulation of cytochrome P450 metabolism in rat hepatocytes
1999, European Journal of Pharmacology
Nonparenchymal cells, particularly Kupffer cells, might play an important role in the modulation of xenobiotic metabolism in liver and its pharmacological and toxicological consequences. This intercellular communication via the exchange of soluble factors was investigated in primary rat Kupffer cells and hepatocytes. Freshly isolated rat Kupffer cells were seeded onto cell culture inserts and cocultured with 5 day old serum-free rat hepatocyte monolayer cultures at a ratio of 1:1 for 2 days. Hepatocyte cultures, Kupffer cell cultures or cocultures were treated with 0.1 ng/ml–10 μg/ml lipopolysaccharide (LPS). Within this concentration range, no significant toxicity was observed in either cell type. In LPS-exposed cocultures, tumor necrosis factor α (TNFα) levels rose up to 5 ng/ml within 5 h; nitric oxide (NO) levels increased up to 70 μM within 48 h of treatment, both in a dose-dependent fashion. The release of negative (albumin) and positive (α1-acid-glycoprotein) acute phase proteins from the hepatocytes was strongly down- and up-regulated, respectively. The simultaneous treatment of the cocultures with phenobarbital and LPS (10 ng/ml) or 3-methylcholanthrene and LPS (10 ng/ml) resulted in a strong down-regulation (85%) of the phenobarbital-induced cytochrome P450 (CYP) isoform CYP2B1 in the hepatocytes whereas the 3-methylcholanthrene-induced isoform CYP1A1 was only weakly affected (15%). This specific down-regulation of CYP2B1 was mediated exclusively by TNFα, released from the Kupffer cells. It was not linked with NO release from or inducible NO synthase activity in the hepatocytes. The TNFα release was not affected by the two xenobiotics. Acetaminophen tested in these cocultures showed no direct interaction with the Kupffer cells. The use of liver cell cocultures is therefore a useful approach to investigate the influence of intercellular communication on xenobiotic metabolism in liver.

View all citing articles on Scopus

View full text

Kupffer cell factor mediated depression of hepatic parenchymal cell cytochrome P-450

Abstract

Lancet

Biochem. biophys. Res. Commun.

Biochem. biophys. Res. Commun.

Biochem. Pharmac.

Int. J. Immunopharmac.

J. biol. Chem.

J. biol. Chem.

J. biol. Chem.

Expl Cell Res.

Chem. Biol. Interact.

Int. J. Immunopharmac.

Int. J. Immunopharmac.

Biochem. Pharmac.

Biochem. Pharmac.

Int. J. Immunopharmac.

Pediatrics, N.Y.

Molec. Pharmac.

Drug Metab. Dispos.

J. Cell Biol.